por John R. Fischer
, Senior Reporter | January 28, 2020
Healthcare tech giant Philips finished off fourth-quarter sales in 2019 with more than $6.6 billion (€6 billion), demonstrating a 3 percent rise in sales growth compared to the fourth quarter of 2018.
Income from continuing operations brought in more than $605 million (€550 million), and adjusted EBITA margin increased by 50 basis points to 17.9 percent, a rise from 17.4 percent of sales in Q4 2018. Comparable order intake increased by 3 percent, while adjusted EPS from continuing operations (diluted) increased by 9 percent compared to the same time in 2018. All business segments — which include Diagnosis & Treatment, Connected Care and Personal Health — experienced growth and increased profitability.
“Customers are keen to engage with us, and we see a strong interest in our innovative solutions, but also in the way we contract together in long-term, strategic partnerships,” CEO Frans van Houten told HCB News during a roundtable conference call on the results, adding that “the order book that we start 2020 off with is strong and underpins the momentum for 2020 in a good way.”
1st FDA Approved Handheld Wireless Ultrasound Probe.Currently being used to fight COVID-19 in Wuhan China, South Korea, & within the USA.Features include Lung Ultrasound Scanning, & PACS Compatibility. ( CONTACT US TODAY TO RESERVE INVENTORY )
While mostly positive, fourth quarter results were hampered by income from operations which amounted to over $800 million (€730 million), down from over $845 million (€769 million) in Q4 2018. Operating cash flow also decreased, as did free cash flow from over $1.1 billion to just above $1 billion. van Houten attributed these negatives partially to flat markets, supply chain challenges, and the trade war between the U.S. and China.
“We were able to mitigate some of it, but it still had a net impact of €70 million (over $75 million), which is then close to 50 basis points in the results. It’s not small,” he said. “We have worked hard to change supply chains, but it has required more effort and sometimes it is not easily possible.”
The impact on the full year was a 4 percent increase in sales to over $21 billion (€19.5 billion), compared with 2018. Comparable order intake increased by three percent, though income from continuing operations dropped from above $1.4 billion (over €1.3 billion) to above $1.2 billion (over €1.1 billion) million, and income from operations dropped from over $1.8 billion (over €1.7 billion) to more than $1.7 billion (over €1.6 billion).
Adjusted EBITA margin rose 10 basis points to 13.2 percent for sales, one percent higher than that of 2018, while EPS from continuing operations (diluted) amounted to €1.30, and adjusted EPS from continuing operations increased by 15 percent, compared to 2018, to €2.02. Operating cash flow was over $2.4 billion (more than €2.2 billion), up from more than $1.8 billion (over €1.7 billion), and free cash flow was more than $1.1 billion (more than €1 billion), an increase from just over one billion (€984 million) in 2018. The proposed dividend was €0.85 per share.